This site is intended for US Healthcare Professionals only.
This site is intended for US Healthcare Professionals only.

Baujat et al. Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases. Orphanet Journal of Rare Diseases (2017) 12:123.

Chakkalakal SA et al. Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation. J Bone Miner Res 2016; 31:1666-1675.

Glaser, DL, Kaplan FS. Treatment considerations for the management of fibrodysplasia ossificans progressiva. Clinic Rev Bone Miner Metab 2005; 3: 243-250.

Kaplan FS, et al. The International Clinical Consortium on FOP 2011. The Medical Management of Fibrodysplasia Ossificans Progressiva: Current Treatment Considerations. Proc Intl Clin Council FOP. 2019; 1:1–111.

Kaplan FS, Pignolo RJ, Shore EM. From mysteries to medicines: drug development for fibrodysplasia ossificans progressive. Expert Opin Orphan Drugs. 2013; 1:637–649.

Kaplan FS et al. Fibrodysplasia ossificans progressiva: mechanisms and models of skeletal metamorphosis. Dis Model Mech. 2012; 5:756-62.

Kaplan FS et al. Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva. J Bone Joint Surg Am. 2010; 92:686-91.

Kaplan FS et al. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat 2009;30:379-90.

Kaplan FS. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat. 2009 March; 30(3):379–390.

Kaplan FS et al. Fibrodysplasia ossificans progressive. Best Pract Res Clin Rheumatol. 2008; 22(1):191–205.

Kaplan et al. Skeletal metamorphosis in fibrodysplasia ossificans progressiva (FOP). J Bone Miner Metab. 2008; 26:521–530.

Kaplan FS, Xu M, Glaser DL, et al. Early diagnosis of fibrodysplasia ossificans progressiva (FOP). Pediatrics 2008;121: e1295–1300.

Kaplan FS and Glaser DL. Thoracic insufficiency syndrome in patients with fibrodysplasia ossificans progressive. Clin Rev Bone Miner Metabol 2005;3:213-216.

Kaplan FS. Fibrodysplasia Ossificans Progressiva. A Historical Perspective. Clin Rev Bone Miner Metabol 2005;3:179–181.

Kaplan FS, et al. The phenotype of fibrodysplasia ossificans progressive. Clin Rev Bone Miner Metab. 2005; 3:183–188.

Kitterman JA, et al. Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva. Pediatrics 2005; 116; e654.

Levy CE, Lash AT, Janoff HB, Kaplan FS. Conductive hearing loss in individuals with fibrodysplasia ossificans progressiva. Am J Audiol. 1999; 8:29–33.

OrphaNet: Fibrodysplasia ossificans progressiva. Accessed June 13, 2018.

Pignolo RJ et al. Joint-specific risk of impaired function in fibrodysplasia ossificans progressiva (FOP). Bone 2018; 109:124-133.

Pignolo RJ et al. The natural history of flare-ups in fibrodysplasia ossificans progressiva (FOP): A comprehensive global assessment. Bone Miner Res 2016: 31(3) 650-656.

Pignolo RJ et al. Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons. Pediatr Endocrinol Rev. 2013 June; 10(0 2): 437–448.

https://www.ncbi.nlm.nih.gov/pubmed/23858627

Pignolo RJ. Fibrodysplasia ossificans progressiva: Clinical and genetic aspects. Orphanet Journal of Rare Diseases 2011, December; 6:80

https://www.ncbi.nlm.nih.gov/pubmed/22133093

Shore EM. Fibrodysplasia ossificans progressiva: a human genetic disorder of extraskeletal bone formation, or–how does one tissue become another? Wiley Interdiscip Rev Dev Biol. 2012; 1(1):153-65.

Shore EM, Kaplan FS. Inherited human diseases of heterotopic bone formation. Nat Rev Rheumatol 2010; Sep; 6(9):518-27.

Shore E, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. 2006; 38:525–7

Shore EM, Feldman GJ, Xu M, Kaplan FS. The genetics of fibrodysplasia ossificans progressive. Clin Rev Bone Miner Metabol. 2005; 3(3–4):201–204.

We use cookies to ensure that we give you the best experience on our website. Click here for more information.
Please always consult a healthcare professional if you require healthcare advice or if you have any specific concerns regarding Fibrodysplasia Ossificans Progressiva. The information provided here is not intended to replace professional advice. This website has been developed by Ipsen in collaboration with those living with Fibrodysplasia Ossificans Progressiva and the healthcare professionals who care for them. Ipsen would like to thank everyone for their valuable insights and stories. All names used on this website are not necessarily real names. Visit our website for more information about us, or to contact us directly. Website design and development by Kanga Health Ltd. Website reference NON-US-002031 December 2020